We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options. Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, pegtibatinase (TVT-058), the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development.
Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders.
Because of our patient-centered purpose and recognition that rare disease has no borders, we supported the creation of the Rare Disease Network at Children’s National Rare Disease Institute (CNRDI). The network exists to improve rare disease care in the US and internationally through innovative digital medicine technology and partnerships with rare disease experts.
In our commitment to support caregivers of people living with rare disease, we worked with NORD to establish the Rare Caregiver Respite Program, and with the National Alliance of Caregivers to better understand and help meet the needs of rare caregivers.
We also supported the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy.
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).
One year ago – Mother’s Day 2020, I was two and a half months away from meeting my third and final baby girl. 2020 was a tough year for everyone with the COVID pandemic and living our new normal, but it was about to hit a peak for me when I got news just a month later I would have never fathomed. Read a message from Valarie, baby Delila’s mom
Thomas enjoys many things typical of twelve-year-old kids: sports, time with his friends, and playing video games. But Thomas’ journey has not always followed the typical path for kids his age.
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2021 financial results and provided a corporate update.
RET153
© 2021 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
NewsSAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.
Read the full press release >